NVAX’s comeback attempt: leaner Novavax swings at the next wave

The thesis

Novavax (NVAX) is trying to turn a one-product COVID story into a broader vaccine platform while cutting costs and shoring up cash. In May 2024 it signed a major deal with Sanofi, giving Sanofi rights to co-commercialize Novavax’s protein-based COVID vaccine globally (except some markets) and to develop a combined COVID/flu shot; Novavax received $500 million upfront ($70 million cash plus up to $730 million in milestones and royalties over time).[1][2] It has also been executing a restructuring plan announced in 2023 to cut roughly $300 million in yearly costs, including headcount reductions.[3][4] The bull case is that a steady COVID booster market, a differentiated protein vaccine for people wary of mRNA, and combo products with Sanofi’s backing can support meaningful revenue and reduce the risk of running out of cash.[1][2][3]

💡 Why this matters

COVID isn’t front-page news anymore, but shots are likely sticking around like the yearly flu vaccine. Novavax sits in the middle of a long-term shift where vaccines become a regular adult habit, not just something kids get. Its protein-based approach is more like old-school vaccines, which some people prefer over newer mRNA shots. If Novavax and Sanofi can build reliable yearly COVID and combo (COVID + flu) boosters, this taps into the broader health and genomics trend where better tools and data turn vaccines into a recurring, predictable business instead of a one-off pandemic spike.[1][2][5]

▲ Catalysts

+ Execution of the Sanofi global licensing and co-commercialization deal, including potential milestone payments up to $730 million over the coming years.[1][2]
+ U.S. FDA and other regulators’ decisions on updated 2025–2026 COVID booster formulations, which will shape demand for Novavax’s protein-based shot.[5]
+ Progress updates on Novavax’s combined COVID + flu vaccine programs being developed jointly with Sanofi, including clinical trial data readouts.[1][2]
+ Evidence that cost cuts (targeting roughly $300 million annual savings) are flowing through to smaller cash burn and clearer path to break-even.[3][4]
+ Quarterly earnings and guidance updates, where management details expected 2025–2026 COVID season volumes and revenue under the Sanofi partnership.[1][2]

▼ Risks

! Novavax is still heavily dependent on COVID vaccines; if demand falls faster than expected, revenue could shrink sharply.[1][5]
! The company has a history of cash burn and may need more funding if sales disappoint, which could mean issuing more shares and diluting existing holders.[3][4]
! Big rivals like Pfizer, Moderna, and Sanofi itself can outspend Novavax on marketing, trials, and new products, pressuring prices and market share.[1][2][5]
! Regulatory or safety setbacks in COVID or combo vaccines, or slow trial results, could delay products and damage trust with doctors and patients.[5]

🎯 One thing to take away

Novavax (NVAX) is a classic high-risk, high-drama biotech trying to reinvent itself after the first COVID wave. Its big move was teaming up with Sanofi, one of the vaccine giants, which brings cash up front plus the chance to earn more as sales grow and as a COVID + flu combo shot develops.[1][2] At the same time, Novavax is cutting costs hard to shrink its cash burn.[3][4] If yearly COVID and combo shots become a steady business and Novavax’s protein-based vaccine wins a loyal niche, today’s small market value could look cheap. If demand fades or rivals squeeze it out, the company could struggle again. It’s a name to research more if you’re comfortable with biotech swings and binary outcomes, not a sleepy blue chip.

Sources

Want our premium picks too?

Pro subscribers get our strongest pre-pop ideas + real-time buy-zone alerts.